Tissue Regenix Group PLC Appointment of CEO (5009F)
17 November 2020 - 6:00PM
UK Regulatory
TIDMTRX
RNS Number : 5009F
Tissue Regenix Group PLC
17 November 2020
Tissue Regenix Group plc
Appointment of CEO
Leeds, 17 November 2020 - Tissue Regenix Group (AIM:TRX)
("Tissue Regenix", the "Company" or the "Group") the regenerative
medical devices company, announces that it has appointed Daniel
("Danny") Lee as Chief Executive Officer. Danny joined the Group as
President of U.S. Operations in January 2019. Danny will commence
his new role and join the Board with immediate effect.
Danny, who resides in the United States, has nearly 30 years'
experience in the medical device and biologics industry. Prior to
joining the Group in January 2019, Danny was the Chief Executive
Officer for Scaffold Biologics and Aperion Biologics. His previous
senior management roles included global marketing for
OsteoBiologics (acquired by Smith & Nephew Endoscopy in 1996)
and marketing activities for Regeneration Technologies (now RTI
Surgical), a leading allograft tissue processor. Danny spent the
first ten years of his career in R&D with the U.S. Surgical
Corporation (now Medtronic). Danny received his B.E.S. degree in
Materials Science and Engineering from Johns Hopkins University and
his M.S. in Biomedical Engineering from the University of Alabama
at Birmingham.
Danny will succeed Gareth Jones, who joined the Company in
October 2018 as Chief Financial Officer and was subsequently
appointed Interim Chief Executive Officer in August 2019. Gareth
will step down from the Board with immediate effect, and plans to
remain with the Group until the end of 2020 in order to effect an
orderly handover.
Danny Lee, Tissue Regenix's incoming CEO, commented: "I would
like to thank Gareth for his leadership during a transitional
period for the company. I am honoured to be selected to lead this
company. Throughout my career, I have been passionate about
building and growing companies in the regenerative medical space.
During my tenure at the Company, I have had the opportunity to
appreciate the impact created by our proprietary products and the
exceptional capabilities of our team. I look forward to continuing
the growth of our company in a dynamic market, identifying
additional opportunities to innovate, and taking the decisive
actions needed to move our business forward."
Interim Chairman, Jonathan Glenn, commented: "I am delighted to
welcome Danny to the Board of Tissue Regenix as Group CEO. Since
joining us in January 2019, Danny has demonstrated exceptional
leadership skills and was the stand out candidate from a thorough
external recruitment process. I would also like to thank Gareth who
stepped up on an interim basis to CEO in very difficult
circumstances and led the business admirably during this
period."
For more Information:
Tissue Regenix Group plc Tel: 0330 430
Caitlin Pearson - Head of Communications 3073
------------------------------------------ --------------
Stifel Nicolaus Europe Limited (Nominated Tel: 0207 710
Adviser and Broker) 7600
Ben Maddison / Alex Price
------------------------------------------ --------------
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. Tissue Regenix was formed in 2006 when it
was spun-out from the University of Leeds, UK. The Company's
patented decellularisation ('dCELL (R) ') technology removes DNA
and other cellular material from animal and human soft tissue
leaving an acellular tissue scaffold which is not rejected by the
patient's body and can then be used to repair diseased or worn out
body parts. Current applications address many critical clinical
needs such as sports medicine, heart valve replacement and wound
care.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States - 'Tissue Regenix Wound Care Inc.',
January 2016 saw the establishment of joint venture GBM-V, a multi-
tissue bank based in Rostock, Germany.
In August 2017 Tissue Regenix acquired CellRight Technologies
(R) , a biotech company that specializes in regenerative medicine
and is dedicated to the development of innovative osteoinductive
and wound care scaffolds that enhance healing opportunities of
defects created by trauma and disease. CellRight's human
osteobiologics may be used in spine, trauma, general orthopaedic,
foot & ankle, dental, and sports medicine surgical
procedures.
Regulatory disclosures
Daniel Ray Lee (Danny), 59, has been a director or partner of
the following companies or partnerships during the past five
years:
Current directorships/partnerships Directorships/partnerships within
the last 5 years
None Scaffold Biologics, Inc
Aperion Biologics, Inc
There are no further disclosures required in accordance with AIM
Rule 17 and Schedule Two paragraph (g) of the AIM Rules for
Companies.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAEAEFKFSFEFAA
(END) Dow Jones Newswires
November 17, 2020 02:00 ET (07:00 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Apr 2024 to May 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From May 2023 to May 2024